Non-Small Cell Lung Cancer Coverage from Every Angle

Surfactant Protein D and Clinical Outcomes in Lung Cancer

Umeda et al, of Sapporo Medical University School of Medicine, Japan, reported that the use of serum surfactant protein D level may prove to be a marker of efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs). The investigators, who discovered that surfactant protein D appears to downregulate TKI-sensitive and TKI-resistant EGFR-mutant signaling, published their results in Oncogene. In a previous study, they showed that surfactant protein D blocked ligand binding to EGFR, suppressing wild-type EGFR signaling.

Among the various effects of this protein on EGFR mutations in lung adenocarcinoma, the authors featured a retrospective analysis of 121 patients with this type of lung cancer. They focused on the link between serum surfactant protein D levels and clinical outcomes in those patients treated with TKIs who harbored EGFR mutations (Ex19del or L858R). There appeared to be fewer distant metastases as well as prolonged progression-free and overall survival in those who had high serum levels of surfactant protein D.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.